Sponsors (41)
The bill clarifies and accelerates FDA regulatory definitions to improve predictability for developers and reduce ambiguity for patients and clinicians, but does so by shortening public input, creating potential new compliance costs, and pressuring FDA resources and implementation timelines.
Drug developers, scientists, hospitals, and health systems will face faster and more predictable FDA regulatory reviews because the rule updates align regulations with the 2023 statutory amendments, reducing delays in submissions and approvals.
Patients (including those with chronic conditions) and clinicians will see clearer regulatory definitions for 'nonclinical tests,' reducing ambiguity in drug development and FDA submissions and helping ensure appropriate evidence is considered.
The FDA can implement clarifying changes more quickly because the rule is made immediately effective on publication, shortening the time to apply new standards.
Scientists, researchers, industry stakeholders, and patients will have reduced opportunity for notice-and-comment because the rule takes immediate effect, limiting public input on regulatory changes.
Drug developers, hospitals, and manufacturers may incur new compliance costs as they revise submissions and internal processes to conform to the updated definitions and requirements.
FDA staff and federal employees may face a strained timeline from the one-year deadline, increasing the risk of rushed rulemaking, uneven implementation, or inconsistent enforcement across related provisions.
Based on analysis of 2 sections of legislative text.
Directs FDA to issue an interim final rule within one year to insert and use the statutory definition of “nonclinical test” across specified regulations and make that rule effective immediately.
Requires the FDA to issue an interim final rule within one year that updates multiple FDA regulations to use the statutory term “nonclinical test(s)” (and related phrasing) instead of broader generic references, and to insert the new statutory definition of “nonclinical test” into specified regulatory provisions. The rule must be published within one year of enactment and will be effective immediately upon publication without the usual prior notice-and-comment good-cause finding; the bill also renames an existing statutory subsection on clinical trial diversity.
Introduced April 10, 2025 by Buddy Carter · Last progress April 10, 2025